Article Type
Changed
Wed, 11/22/2023 - 13:01

Key clinical point: The prognosis for patients with breast cancer (BC) who develop contralateral axillary lymph node metastasis (CAM) is similar to that for patients developing oligometastatic disease (OM) but is considerably worse than that for patients developing locoregional recurrence (LRR).

Major finding: The overall survival (OS) and progression-free survival (PFS) outcomes in patients with CAM were similar to those in patients with OM (P = .07 and P = .97, respectively) but were significantly worse than those in patients with LRR (hazard ratio [HR] 0.47, P = .0097; and HR 0.39, P < .0001).

Study details: Findings are from a single-center retrospective study including 299 patients with BC, of whom 29, 180, and 90 patients developed CAM, OM, and LRR respectively.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhao Q et al. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease. Breast. 2023 (Oct 7). doi: 10.1016/j.breast.2023.103589

 

 

 

 

Publications
Topics
Sections

Key clinical point: The prognosis for patients with breast cancer (BC) who develop contralateral axillary lymph node metastasis (CAM) is similar to that for patients developing oligometastatic disease (OM) but is considerably worse than that for patients developing locoregional recurrence (LRR).

Major finding: The overall survival (OS) and progression-free survival (PFS) outcomes in patients with CAM were similar to those in patients with OM (P = .07 and P = .97, respectively) but were significantly worse than those in patients with LRR (hazard ratio [HR] 0.47, P = .0097; and HR 0.39, P < .0001).

Study details: Findings are from a single-center retrospective study including 299 patients with BC, of whom 29, 180, and 90 patients developed CAM, OM, and LRR respectively.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhao Q et al. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease. Breast. 2023 (Oct 7). doi: 10.1016/j.breast.2023.103589

 

 

 

 

Key clinical point: The prognosis for patients with breast cancer (BC) who develop contralateral axillary lymph node metastasis (CAM) is similar to that for patients developing oligometastatic disease (OM) but is considerably worse than that for patients developing locoregional recurrence (LRR).

Major finding: The overall survival (OS) and progression-free survival (PFS) outcomes in patients with CAM were similar to those in patients with OM (P = .07 and P = .97, respectively) but were significantly worse than those in patients with LRR (hazard ratio [HR] 0.47, P = .0097; and HR 0.39, P < .0001).

Study details: Findings are from a single-center retrospective study including 299 patients with BC, of whom 29, 180, and 90 patients developed CAM, OM, and LRR respectively.

Disclosures: This study did not receive any specific funding. The authors declared no conflicts of interest.

Source: Zhao Q et al. Contralateral axillary lymph node metastasis in breast cancer: An oligometastatic-like disease. Breast. 2023 (Oct 7). doi: 10.1016/j.breast.2023.103589

 

 

 

 

Publications
Publications
Topics
Article Type
Sections
Disallow All Ads
Content Gating
No Gating (article Unlocked/Free)
Alternative CME
Disqus Comments
Default
Article Series
Clinical Edge Journal Scan, Breast Cancer November 2023
Gate On Date
Tue, 12/20/2022 - 14:15
Un-Gate On Date
Tue, 12/20/2022 - 14:15
Use ProPublica
CFC Schedule Remove Status
Tue, 12/20/2022 - 14:15
Hide sidebar & use full width
render the right sidebar.
Conference Recap Checkbox
Not Conference Recap
Clinical Edge
Display the Slideshow in this Article
Medscape Article
Display survey writer
Reuters content
Disable Inline Native ads
WebMD Article